AbbVie announced that the Food and Drug Administration (FDA) has approved Humira (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease for patients ≥6 years old when certain other treatments were inadequate.
The FDA has granted tentative approval for Uceris (budesonide) rectal foam for the induction of remission in patients with active mild-to-moderate distal ulcerative colitis (UC).
The Food and Drug Administration has approved Movantik (naloxegol; AstraZeneca) for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
There is limited data on the effectiveness of opioid analgesics in relieving symptoms such as abdominal pain and diarrhea associated with IBD.
ased on placebo-controlled trials, the safety and efficacy of adalimumab therapy in UC patients has been reported up to Week 52.
The FDA has issued an alert regarding an ingredient commonly found in gluten-free products that may cause anaphylaxis in patients with a legume allergy.
Moderately-to-severely active ulcerative colitis.
Review this chart for quick information when you need it.